Black Diamond Forges Global Pact with Servier for BDTX-4933, a Next-Gen Cancer Fighter

March 19, 2025

DENVER, Colo., Mar 19, 2025 (247marketnews.com)- Diamond Therapeutics (NASDAQ:BDTX) and Servier struck a worldwide licensing deal for BDTX-4933, a promising targeted therapy poised to tackle RAF/RAS-mutant solid tumors. This partnership amplifies Servier’s mission to deliver innovative cancer treatments and hands Black Diamond a hefty financial boost to fuel its MasterKey vision.

Claude Bertrand, Servier’s Executive VP of R&D, stated, “At Servier, we are dedicated to transforming patient care in areas with significant unmet needs. Our partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies, as we believe we can serve more people by helping the right patients find the right treatment, at the right time. We look forward to accelerating the development of this therapy as a potential best-in-class treatment for cancer patients.”

BDTX-4933, a small molecule crafted by Black Diamond, targets both RAS mutations and RAF alterations—a dual-threat approach with best-in-class potential. Now in Phase 1 trials, it’s being tested for safety, dosing, and antitumor punch in patients with advanced or metastatic cancers, including non-small cell lung cancer (NSCLC), harboring BRAF, CRAF, or NRAS mutations. Servier will steer its development and global rollout, eyeing NSCLC and beyond, aiming to fill gaping unmet needs in oncology.

Mark Velleca, M.D., Ph.D., Black Diamond’s President and CEO, added, “This agreement supports our mission to advance oral cancer therapies designed to give patients the opportunity for longer, healthier, and more active lives. Servier’s commitment to innovation and deep expertise in oncology make it an ideal partner for Black Diamond as we work to develop breakthrough cancer treatments.”

Black Diamond pockets an upfront $70 million fee, with up to $710 million in milestone payments tied to development and sales, plus tiered royalties on global net sales. For Servier, it’s a strategic grab of a cutting-edge asset; for Black Diamond, it’s a cash infusion to turbocharge its mutation-hunting pipeline.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BDTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.